Versant Capital Management, Inc Celldex Therapeutics, Inc. Transaction History
Versant Capital Management, Inc
- $637 Million
- Q2 2025
A detailed history of Versant Capital Management, Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 214 shares of CLDX stock, worth $4,806. This represents 0.0% of its overall portfolio holdings.
Number of Shares
214
Previous 88
143.18%
Holding current value
$4,806
Previous $1,000
300.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CLDX
# of Institutions
189Shares Held
69.4MCall Options Held
220KPut Options Held
310K-
Wellington Management Group LLP Boston, MA8.35MShares$188 Million0.03% of portfolio
-
Kynam Capital Management, LP Princeton, NJ6.5MShares$146 Million9.94% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$105 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.9MShares$87.6 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$84.3 Million1.45% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.05B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...